Close Menu

NEW YORK – OraSure Technologies reported after the close of the market on Monday that its fourth quarter revenues rose 27 percent year over year due to strong sales of molecular sample collection devices.

For the three months ended Dec. 31, 2020, the point-of-care diagnostic testing and specimen collection device manufacturer reported revenues of $62.9 million, up from $49.7 million a year ago and above the analysts' average estimate of $57.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.